Mycophenolate isn't great for vaccine immunogenicity, but withholding MMF for one week after both doses of recombinant zoster vaccine boosts Ab titres ++ in this Brazilian RCT. A week off post-vaccine: definitely worth considering in stable disease #ACR24 ABST0247 @RheumNow https://t.co/lajS5DzRbD

• https://x.com/drdavidliew/status/1857803007662157981/photo/1

Safety data reassuring with UPA 15 mg vs PBO No UPA MACE events, low VTE Ab#0770 @RheumNow #ACR24 https://t.co/lMf2dCz2RX https://t.co/3DnPIoVOt8

• https://x.com/ericdeinmd/status/1857795698420273349/photo/1
• https://twitter.com/ericdeinmd/status/1857794819352825977

Upadacitinib (UPA), a new oral treatment option for GCA? Dr. Peter Merkel discusses SELECT-GCA. UPA15 + 26-week GC taper >> PBO with a 52-week GC taper for GCA remission. #ACR24 #ACRBest @RheumNow ABST#0770 https://t.co/UbQLVA8X7r

• https://x.com/JihaRheum/status/1857796768035213421/photo/1

Major update in tx for GCA beyond Toci SELECT-GCA showed upadacitinib 15mg daily achieving higher rates of remission with SHORTER (26wk) steroid use compared to placebo (52wk) No significant adverse safety signal w JAKi including MACE/malignancy @RheumNow #ACR24 Abstract 0770 https://t.co/45D0Txed2N

• https://x.com/Dr_Brian_MD/status/1857798289459961856/photo/1
• https://x.com/Dr_Brian_MD/status/1857798289459961856/photo/1

SELECT trial noted reduction in CV death, MI and stroke in obese pts without diabetes (other benefits: reduction in waist circumference, BP, lipids) @rheumnow # ACR24 https://t.co/GPK4Vg5bOt

• https://x.com/KDAO2011/status/1857799228661064122/photo/1
• https://x.com/KDAO2011/status/1857799228661064122/photo/1

Results from SELECT-GCA ➡️UPA 15mg + 26W GC taper demonstrates superior efficacy & reduced GC use vs PBO + 52W GC taper ➡️No new safety signals Is UPA the new kid on the block in #GCA? Ab0770 #ACRBest #ACR24 @RheumNow https://t.co/pHzozYiid5

• https://x.com/DrMiniDey/status/1857796013395697830/photo/1

The TAPIR Trial on GPA shows higher (15.5%) relapse in the 0 mg prednisone arm vs. 4.2% in the 5 mg arm (OR 4.22), but does not impact PROs. Key finding: benefit of 5 mg/day seen only in non-rituximab regimens (20% vs. 2.6%, OR 9.50). Abstr#0774 Plenary 1 @RheumNow #ACR24… https://t.co/5DjW5Zwh0J https://t.co/UnsVPzJfs6

• https://x.com/i/web/status/1857791986553540805
• https://x.com/synovialjoints/status/1857791986553540805/photo/1

SELECT-GCA: Upa in GCA Merkel Upa 15 mg v 7.5 v PBO w slower GC taper 70% new onset, 30% relapse. Few prev on IL6 Primary endpt: sustained remission at w52- UPA 15 mg beats PBO (p=0.0019) 34% relapse in UPA vs 60% PBO Less steroids, longer time to flare @RheumNow #ACR24 #ACRBest https://t.co/1OV2889Ny0

• https://x.com/ericdeinmd/status/1857794819352825977/photo/1
• https://x.com/ericdeinmd/status/1857794819352825977/photo/1
• https://x.com/ericdeinmd/status/1857794819352825977/photo/1

Real-world data from @k_lauper's Jak-pot study (>9000 RA pt) on how quickly b/tsDMARDs work: JAKi, TNFi quicker than tocilizumab, abatacept Even though they all get to a similar place eventually, some get there quicker (but worth any safety tradeoffs?) #ACR24 ABST0501 @RheumNow https://t.co/YVpTBMe3gi

• https://x.com/drdavidliew/status/1857781834710417896/photo/1

Like we've seen in many parts of the world, RA prescribing in Germany is moving away from JAKi, in response to regulatory safety warnings. Whether all of this is appropriate or not, we'll have to see... #ACR24 ABST0503 @RheumNow https://t.co/VSqdCz6zc5

• https://x.com/drdavidliew/status/1857779835030089902/photo/1